文献速递肝病

PCSK7、PNPLA3与TM6SF2变异增加遗传性血色病肝硬化风险

Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosis.
PubMed 文献 · Aliment Pharmacol Ther · 2021-02-10

在1319例来自六个欧洲国家的C282Y纯合子中,评估PCSK7、PNPLA3、TM6SF2等基因变异与肝硬化风险的关联。固定效应荟萃分析显示,PCSK7:rs236918、PNPLA3:rs738409和TM6SF2:rs58542926均显著增加肝硬化风险,三者合并的人群归因分数为24.0%。

要点

  • PCSK7:rs236918、PNPLA3:rs738409和TM6SF2:rs58542926与C282Y纯合子肝硬化风险显著相关。
  • 三种变异合并的人群归因分数为24.0%,提示联合检测有助于风险分层。
  • 在具有肝脏组织学资料的亚组中,上述关联仍然显著。

核心结论

  • PCSK7:rs236918与C282Y纯合子肝硬化风险的关联在更大样本中得到证实。
  • PNPLA3:rs738409和TM6SF2:rs58542926被确立为显著的额外危险因素。
  • 对C282Y纯合子进行更详细的基因检测有助于风险分层并指导未来管理。

研究设计与样本

  • 研究纳入来自六个欧洲国家的1319例C282Y纯合子,其中171例(13.0%)患有肝硬化。
  • 对PCSK7、PNPLA3、TM6SF2、MBOAT7和HSD17B13变异进行基因分型,并调整年龄和性别。
  • 采用固定效应荟萃分析合并各国调整后的汇总数据。
  • 事后在具有肝脏组织学资料的131例(76.6%)病例和299例(26.0%)对照中进行关联检验。

主要发现

  • PCSK7:rs236918与肝硬化风险显著相关(OR=1.52,95%CI 1.06-2.19,P=0.022,I²=0%)。
  • PNPLA3:rs738409与肝硬化风险显著相关(OR=1.60,95%CI 1.22-2.11,P=7.37×10⁻⁴,I²=45.5%)。
  • TM6SF2:rs58542926与肝硬化风险显著相关(OR=1.94,95%CI 1.28-2.95,P=1.86×10⁻³,I²=0%)。
  • 在具有肝脏组织学资料的亚组中,上述关联仍然显著。

关键数值与推荐

  • PCSK7:rs236918的人群归因分数为5.6%。
  • PNPLA3:rs738409的人群归因分数为13.8%。
  • TM6SF2:rs58542926的人群归因分数为6.5%。
  • 三种变异合并携带的人群归因分数为24.0%。

临床怎么用

  • 对C282Y纯合子可考虑检测PCSK7、PNPLA3和TM6SF2变异以辅助肝硬化风险分层。
  • 联合携带三种变异者肝硬化风险更高,或需更密切监测。

局限性

  • 事后组织学亚组分析仅纳入部分病例和对照。
  • 研究仅涉及欧洲人群,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cirrhosis develops in <10% of individuals homozygous for the C282Y variant in the homeostatic iron regulator (HFE) gene. Carriage of PCSK7:rs236918 is associated with an increased risk of cirrhosis in this population. AIM: To determine if genetic variants significantly associated with the risk of alcohol- and NAFLD-related cirrhosis also modulate the cirrhosis risk in C282Y homozygotes. METHODS: Variants in PCSK7, PNPLA3, TM6SF2, MBOAT7 and HSD17B13 were genotyped in 1319 C282Y homozygotes, from six European countries, of whom 171 (13.0%) had cirrhosis. Genotypic and allelic associations with the risk for developing cirrhosis were assessed, adjusting for age and sex. Fixed effects meta-analyses of the adjusted summary data for each country were performed. Post hoc association testing was undertaken in the 131 (76.6%) cases and 299 (26.0%) controls with available liver histology. RESULTS: Significant associations were observed between PCSK7:rs236918 (OR = 1.52 [95% CI 1.06-2.19]; P = 0.022; I2 = 0%); PNPLA3:rs738409 (OR = 1.60 [95% CI 1.22-2.11]; P = 7.37 × 10-4 ; I2 = 45.5%) and TM6SF2:rs58542926 (OR = 1.94 [95% CI 1.28-2.95]; P = 1.86 × 10-3 ; I2 = 0%) and the cirrhosis risk in C282Y homozygotes. These findings remained significant in the subpopulation with available liver histology. The population-attributable fractions were 5.6% for PCSK7:rs236918, 13.8% for PNPLA3:rs738409, 6.5% for TM6SF2:rs58542926 and 24.0% for carriage of all three variants combined. CONCLUSIONS: The risk of cirrhosis associated with carriage of PCSK7:rs236918 was confirmed in this much larger population of C282Y homozygotes. In addition, PNPLA3:rs738409 and TM6SF2:rs58542926 were established as significant additional risk factors. More detailed genetic testing of C282Y homozygotes would allow risk stratification and help guide future management.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Buch S, Sharma A, Ryan E, et al. Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosis. Aliment Pharmacol Ther. 2021. PMID: 33565643. doi:10.1111/apt.16252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。